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Abstract 
Objectives 
To evaluate diagnostic accuracy of a high-sensitivity cardiac troponin I (hs-cTnI) assay for acute 
coronary syndromes (ACS) in the Emergency Department (ED). The assay has high precision at low 
concentrations and can detect cTnI in 96.8% of healthy individuals.  
Methods 
In successive prospective multi-center studies (‘testing’ and ‘validation’) we included ED patients 
with suspected ACS. We drew blood for hs-cTnI (Singulex Clarity® cTnl, 99th percentile 8.67ng/L, limit 
of detection [LoD] 0.08ng/L) on arrival. Patients also underwent hs-cTnT (Roche Elecsys) testing over 
≥3h. The primary outcome was an adjudicated diagnosis of ACS, defined as acute myocardial 
infarction (AMI; prevalent or incident), death, or revascularization within 30 days. 
Results 
The testing and validation studies included 665 and 2,470 patients respectively, of which 94 (14.1%) 
and 565 (22.9%)  had ACS. At a 1.5ng/L cut-off, hs-cTnI had good sensitivity for AMI in both studies 
(98.7% and 98.1% respecively) and would have ‘ruled out’ 40.1% and 48.9% patients. However, 
sensitivity was lower for ACS (95.7% and 90.6% respectively). At a 0.8ng/L cut-off sensitivity for ACS 
was higher (97.5% and 97.9%, ‘ruling out’ 28.6% patients in each cohort). The hs-cTnT assay had very 
similar performance at the LoD (24.6% ‘ruled out’, 97.2% sensitivity for ACS). 
Conclusion  
The hs-cTnI assay could immediately ‘rule out’ AMI in 40% patients and ACS in over 25%, with similar 
accuracy to hs-cTnT at the LoD. Because of its high precision at low concentrations, this hs-cTnI assay 
has favourable characteristics for this clinical application.  
Page 4 of 21 
 
Background 
 
Chest pain accounts for approximately 6% of all ED attendances and for over one quarter of acute 
medical hospital admissions (1). Acute coronary syndrome (ACS) is the most common diagnosis 
suspected, which usually requires patients to undergo serial cardiac troponin (cTn) testing over 
several hours. As the majority of patients have non-cardiac diagnoses, there is great potential to 
reduce unnecessary resource utilization (2).  
With high-sensitivity cTn assays (hs-cTn), the diagnosis of acute myocardial infarction (AMI) 
can be excluded in some patients using a single blood test at the time patients arrive in the 
Emergency Department (ED). Existing evidence suggests that AMI can be ‘ruled out’ in patients with 
hs-cTn concentrations below the limit of detection (LoD) of the assay, who have no evidence of ECG 
ischaemia, especially if time from symptom onset is >3 hours (3–8). This strategy relies on the use of 
hs-cTn concentrations below the functional sensitivity of the assay, meaning that the precision is 
suboptimal. This is a concern for laboratories, which face a substantial challenge to ensure 
appropriate quality control. To overcome this challenge, we will require hs-cTn assays with improved 
precision at low concentrations. 
 In this work, we aimed to evaluate the diagnostic accuracy of a one-test ‘rule out’ strategy 
using the Singulex hs-cTnI assay (Singulex Clarity, Alameida, United States), which has excellent 
precision at very low cardiac troponin concentrations, using thresholds below the 99th percentile in 
the ED.  
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Methods 
Design and setting 
Testing study 
We conducted a prospective diagnostic test accuracy study at two centres in the United Kingdom.  
The current analysis is a pre-planned sub-study within a wider programme of research, called the 
Bedside Evaluation of Sensitive Troponin (BEST) study. The National Research Ethics Service granted 
ethical approval (reference 14/NW/1344) and all participants provided written informed consent.  
The study was prospectively registered on the UK National Institute for Health Research Portfolio 
(reference UKCRN 18000).  
Validation study 
We validated our findings using data from the Advantageous Predictors of Acute Coronary 
Syndromes (APACE) study, which is also a prospective diagnostic test accuracy study at 12 centers in 
5 European countries (trial registration NCT00470587). 
Study participants 
In the testing (BEST) study, we included adults (aged >18 years) who presented to the ED with pain, 
discomfort of pressure in the chest, epigastrium, neck, jaw or upper limb without an apparent non-
cardiac source, which warranted investigation for possible ACS in the opinion of the treating 
physician. Patients with peak symptoms occurring >12h before enrolment, those with unequivocal ST 
elevation myocardial infarction (STEMI), those with another medical condition requiring hospital 
admission and patients lacking the mental capacity to provide written informed consent were 
excluded.  
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The validation (APACE) study included patients aged >18 years presenting to the ED with 
chest pain at rest occurring within the previous 12 hours, who had a suspected diagnosis of ACS. 
Patients were excluded if they had cardiogenic shock or end-stage kidney disease requiring dialysis. 
All patients provided written informed consent.  
 
Data collection and laboratory analysis 
Testing study 
We recorded comprehensive clinical data using a bespoke case report form, which the treating 
physician was asked to complete at the time of initial assessment. These data included details of 
patients’ symptoms, previous history, vital signs, physical examination findings and ECG 
interpretation. Forms were scanned and data were automatically extracted using Teleform 
(OpenText, London). We then undertook manual source data verification for 100% of the data, 
followed by a further process of data validation and cleaning.  
Blood was drawn at the time of arrival in the ED and at least 3 hours later. Routine clinical 
samples were analysed using the hs-cTnT assay (Roche Diagnostics Elecsys using the Cobas e602 or 
Cobas 801 instruments, 99th percentile 14ng/L overall, 16ng/L in males, 9ng/L in females (9); limit of 
detection 5ng/L; limit of blank 3ng/L; co-efficient of variation <10% at 5ng/L. Results were reported 
down to 3ng/L. During the study period, at Manchester Royal Infirmary a CV of 8.2% was achieved 
with Randox hs-cTnT control at a concentration of 11.5ng/L; a CV of 2.3% at a concentration of 
29.2ng/L using Roche Precicontrol Troponin; and a CV of 1.9% at a concentration of 2230ng/L. At St 
George’s NHS Foundation Trust, a CV of 8.3% was achieved at a mean hs-cTnT concentration of 
6.1ng/L using the Randox hs-cTnT control).  
For research purposes, additional blood samples were also drawn into serum blood collection 
tubes at the time of arrival in the ED and 3 hours (+/- 30 minutes) later. Within 30 minutes of 
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collection, the samples were centrifuged at 2,500xg for 10 minutes. Serum was aliquoted and stored 
at -70oC or below within 4 hours of blood collection. These previously unthawed serum samples were 
then tested in batches for hs-cTnI using the Singulex Clarity® assay. This assay uses an innovative 
single molecule counting technology to achieve excellent analytical sensitivity and precision (99th 
percentile 8.67ng/L overall, 9.23ng/L in men and 8.76ng/L in women; LoD 0.08ng/L; co-efficient of 
variation <10% at 0.53ng/L (10)). The assay can detect cTnI concentrations in 96.8% of apparently 
healthy individuals (11). Manufacturer’s instructions state that the assay is stable with up to three 
freeze-thaw cycles (12). Current practice recommendations state that hs-cTn concentrations should 
be reported in ng/L, in whole numbers (13). Because of the nature of the Singulex Clarity assay 
(which has an LoD of 0.08ng/L and previously validated cut-offs of 0.8ng/L and 1.5ng/L), we have 
reported results to two decimal places in this analysis. 
 
Validation study 
Data collection was similar in the validation study. Details of the patients’ medical history, physical 
examination and ECG interpretation were prospectively recorded at the time of arrival. All patients 
underwent blood sampling at the time of ED arrival. Serum was extracted and frozen at -80oC 
pending subsequent analysis for Singulex Clarity hs-cTnI.  
  
Outcomes 
The primary outcome was a diagnosis of ACS.  ACS was defined as either type 1 AMI occurring during 
the initial hospital admission (prevalent AMI) or incident major adverse cardiac events (MACE) 
occurring within 30 days.  MACE included death (all cause), incident type 1 AMI and coronary 
revascularization (including either percutaneous coronary intervention or coronary artery bypass 
grafting).  Outcomes were adjudicated by two independent investigators based on all available 
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clinical data up to 30 days after presentation but blinded to hs-cTnI concentrations. The diagnosis of 
type 1 AMI was assigned in accordance with the third universal definition (14), using hs-cTnT 
concentrations as the reference standard. The diagnosis of type 1 AMI alone was considered a 
secondary outcome.  
 
Follow up  
We followed up all patients after 30 days, by: (a) verifying mortality status based on electronic 
records and establishing the registered cause of death for patients who had died; (b) checking all 
available electronic patient records; and (c) personal contact by telephone, email or in person. If 
patients remained persistently uncontactable we contacted their general practitioner (GP). Follow up 
was considered appropriate if the patients GP had been in contact with the patient during the follow 
up period and was able to provide sufficient information regarding ED attendances, hospital 
admissions, investigations and episodes of chest pain.  
 
Statistical analysis 
We analysed the diagnostic accuracy of the hs-cTnI assay using the blood sample drawn at the time 
of arrival (T0). We evaluated the following cut-offs: the limit of detection of the assay (0.08ng/L); the 
optimal cut-off to ‘rule out’ stable coronary artery disease in two recent studies: 0.8ng/L (15) and 
1.5ng/L (16); and the 99th percentile (8.67ng/L). For reference, we compared the diagnostic accuracy 
of the hs-cTnI assay to the hs-cTnT assay that was used in practice during the study (Roche 
Diagnostics Elecsys), using the T0 samples. For the hs-cTnT assay, we used the limit of detection 
(5ng/L) as the ‘rule-out’ cut-off, as has previously been extensively validated (5,17). 
 Test characteristics including sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) together with respective 95% confidence intervals (95% CI) were 
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calculated to assess the diagnostic accuracy. Paired comparison of diagnostic accuracy measures was 
performed with McNemar’s test. Additionally, we calculated areas under the receiver operating 
characteristic (ROC) curves according to the method described by De Long (18). Statistical analyses 
were undertaken using SPSS version 23.0 (SPSS Inc, Chicago, Illinois) and MedCalc version 13.1.2.0 
(Mariakerke, Belgium).  
 
Sample size 
Assuming that the prevalence of the primary outcome is approximately 10%, that the specificity of a 
troponin-based algorithm is approximately 90% and that we would identify an algorithm with 100% 
sensitivity, a sample of 605 patients would ensure that the lower bounds of the 95% confidence 
intervals were >90% for sensitivity and >99% for negative predictive value. Estimating that 5% may 
be lost to follow up or have missing data, we therefore set out to include a minimum of 650 
participants in the testing study. As we are presenting a secondary analysis from the validation study, 
no a priori sample calculation was undertaken for this analysis in the validation study. 
 
Results 
Testing study 
We included a total of 722 patients, of which 665 had sufficient data for inclusion in this analysis. Of 
the eligible participants, 77 (11.5%) had an adjudicated diagnosis of AMI on the initial admission and 
a further 17 (2.6%) developed a major adverse cardiac event (death, AMI or coronary 
revascularization) within 30 days. Thus, a total of 94 (14.1%) patients were considered to have ACS 
(Figure 1). The baseline characteristics of participants are shown in Table 1. 
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 All 665 patients had cTnI concentrations above the limit of detection of the hs-cTnI assay at 
the time of presentation to the ED. The test characteristics of the assay at the selected cut-offs are 
shown in Table 2. Using hs-cTnI alone (without accounting for ECG ischemia), a threshold of 1.5ng/L 
produced a sensitivity of 98.7% for AMI with 99.6% NPV. This strategy would have allowed 267 
(40.2%) patients to have AMI ‘ruled out’ with a single blood test at time of presentation. If AMI was 
only ruled out in patients without ECG ischemia, sensitivity remained 98.7% but the proportion of 
patients ‘ruled out’ dropped marginally to 38.2%. 
 In comparison, an hs-cTnT concentration below 5ng/L at the time of arrival in the ED had a 
sensitivity of 98.6% (95% CI 92.6 – 100.0%) for AMI, with an NPV of 99.6% (95% CI 97.5 – 100.0%) and 
specificity 46.7% (95% CI 42.6 – 50.8%). This strategy would have allowed AMI to be immediately 
‘ruled out’ in 40.9% patients. Considering the diagnosis of ACS, this strategy had a sensitivity of 97.8% 
(95% CI 92.2 – 99.7%) and NPV 99.3% (97.2 – 99.8%).  
If only patients with no ECG ischemia were ‘ruled out’, this hs-cTnT cut-off gave a sensitivity 
of 98.6% (95% CI 92.6 – 100.0%), NPV 99.6% (95% CI 97.4 – 99.9%) and specificity 44.3% (95% CI 40.2 
– 48.4%) for AMI. For ACS, the sensitivity was identical (97.8%, 95% CI 92.2 – 99.7%) and NPV 99.2% 
(95% CI 97.0 – 99.8%). This strategy would have allowed 38.9% patients to have AMI immediately 
‘ruled out’.  
 Stratifying the analysis by time from symptom onset, we did not identify any trend towards 
lower sensitivity and NPV when these rule-out strategies were employed in patients who presented 
within 3 hours of symptom onset (Supplementary Table 1). Similarly, there was no suggestion that 
restricting the use of these rule out strategies to those who presented >3 hours after symptom onset 
would increase sensitivity and NPV (Supplementary Table 2). There was also no suggestion that 
patient sex affected diagnostic accuracy, although a smaller proportion of men would have been 
‘ruled out’ at each cut-off evaluated (Supplementary Table 3). 
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Validation study 
A total of 2,470 patients were included in the validation study, of which 565 (22.9%) met criteria for 
ACS. Baseline characteristics are shown in Table 1 and were notably similar to those in the testing 
study, albeit with a higher prevalence of hypertension and more late presenters (>6h from symptom 
onset).  
 Diagnostic accuracy was also broadly similar to the testing study. At a 0.8ng/L cut-off, 28.6% 
patients would have been ‘ruled out’, achieving a sensitivity of 97.9% for ACS and 100.0% for AMI 
(Table 2). Using the 1.5ng/L cut-off, 48.9% patients would have been immediately ‘ruled out’. 
Sensitivity remained high for AMI at 98.1% but was lower for ACS (90.6%). If only patients with no 
ECG ischemia were considered ‘ruled out’, sensitivity for ACS increased to 92.2% (Table 3). There was 
no suggestion that time from symptom onset affected diagnostic accuracy at these cut-offs 
(Supplementary Tables 1 and 2). 
For comparison, using the LoD (5ng/L) of the Roche hs-cTnT assay would have ‘ruled out’ 
24.6% patients, achieving a sensitivity of 97.2% (95% CI 95.4 – 98.4%) for ACS with an NPV of 97.4% 
(95% CI 95.8 – 98.4%). For AMI, this strategy had 99.7% sensitivity (95% CI 98.5 – 100.0%) with 99.8% 
NPV (95% CI 98.8 – 100.0%).  
 
Discussion 
Our findings demonstrate that the Singulex Clarity hs-cTnI assay could be used to rule out ACS in the 
ED following a single blood test at the time of arrival. In our initial testing study, a threshold of 
1.5ng/L gave very similar sensitivity and NPV to the limit of detection (5ng/L) of the Roche hs-cTnT 
assay and would have ‘ruled out’ a very similar proportion of patients. In the validation study, the hs-
cTnI assay had high sensitivity for AMI at 1.5ng/L but lower sensitivity for ACS (which, in this study, 
was defined as AMI or MACE within 30 days). However, the diagnostic accuracy of the hs-cTnI assay 
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at a 0.8ng/L cut-off was very similar to the Roche hs-cTnT assay at the LoD (5ng/L). With the Roche 
hs-cTnT assay, the European Society of Cardiology has recommended use of the 5ng/L cut-off in 
practice to immediately ‘rule out’ AMI (6), although this recommendation is restricted to patients 
who present >3 hours after symptom onset. Our analysis did not detect any signal to suggest that 
this diagnostic strategy had a lower sensitivity among patients who present within 3 hours of 
symptom onset, but that analysis did have limited statistical power. Therefore, it would still seem 
prudent to exercise caution in early presenters. 
These findings demonstrate that the Singulex Clarity cTnI assay (hs-cTnI) can achieve similar 
diagnostic performance to the Roche hs-cTnT assay for single test ‘rule out’. However, while both 
assays have similar diagnostic accuracy, the Singulex assay has the advantage of offering superior 
precision at low troponin concentrations. This is likely to help with the challenge of ensuring 
adequate quality control for high-sensitivity troponin assays at low concentrations, below the 99th 
percentile. Furthermore, this validation of the diagnostic performance of the hs-cTnI assay in the 
acute environment will facilitate its future use in routine clinical practice.  
As well as the potential value to rule out ACS in the ED, the favourable analytical 
characteristics of the hs-cTnI assay open other exciting possibilities for future patient care. For 
example, the ability to detect extremely low concentrations of cardiac troponin may allow clinicians 
to ‘rule out’ stable coronary artery disease with a single blood test in some patients, obviating the 
need for imaging (16). The assay may have value for the monitoring of apparently healthy individuals 
and predicting future cardiovascular risk (19,20). It may also help to identify patients most likely to 
respond to statin therapy (21). However, to maximize the potential for this assay to be used in acute 
settings, it is important to recognise that the Singulex Clarity® System requires additional 
development, including STAT capability and/or a tracking system, to achieve the required turnaround 
time for ED.  Nevertheless, we have shown in this study that despite these additional future features 
it is possible to utilise the Singulex Clarity cTnI assay (hs-cTnI) for use in ED. 
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We note the following limitations. First, we used hs-cTnT as the reference standard troponin 
assay to adjudicate AMI. It is possible that the diagnostic performance of the Singulex Clarity hs-cTnI 
assay may have appeared better if the same hs-cTnI assay (or even another hs-cTnI assay) had been 
used for adjudication. Similarly, it is possible that the diagnostic performance of the hs-cTnT assay 
reported here may have been lower if a different assay had been used for adjudication. This will, at 
least, tend to provide a conservative estimate of the diagnostic accuracy of the hs-cTnI assay. 
However, as most missed events were MACE occurring within 30 days (and thus unrelated to hs-cTnT 
concentrations at the initial attendance), the impact on our findings is unlikely to be clinically 
important.  
Second, our study is also limited by the short duration of follow-up (30 days). This short 
follow-up duration was used because the study primarily aimed to evaluate diagnostic accuracy, and 
30-day MACE could be taken as a reasonable surrogate for unstable angina, in the absence of an 
accepted reference standard for that diagnosis. However, one key advantage of the Singulex hs-cTnI 
assay may be that detecting smaller cTn concentrations can enhance long-term risk stratification. 
This should be an important focus for future work. 
In conclusion, With the use of a single blood test at the time of arrival in the ED, it is possible 
to ‘rule out’ the diagnosis of ACS in approximately on quarter of patients who have an hs-cTnI 
concentration <0.8ng/L using the Singulex Clarity cTnI assay (hs-cTnI). At a cut-off of 1.5ng/L, the 
assay would ‘rule out’ over 40% patients and retained high sensitivity for AMI, although the assay 
had lower accuracy for MACE at 30 days. Given its high precision at low troponin concentrations, the 
assay has excellent potential for future clinical use in this context.  
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Legends to figures 
 
Figure 1: Participant flow diagram (derivation study) 
Figure 2: Participant flow diagram (validation study) 
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Tables 
Table 1: Baseline characteristics of included patients  
 Testing study Validation study 
 Total 
(n=665) 
ACS 
(n=94) 
No ACS 
(n=571) 
Total  
(n=2,470) 
ACS 
(n=565) 
No ACS  
(n=1,905) 
Age in years, mean 
(SD) 
56 (15) 63 (14) 55 (15) 61 
(16) 
68 
(13) 
59 
(16) 
Men (%) 404 (60.8) 67 (71.3) 337 (59.0) 1,683 
(68.1) 
425 
(75.2) 
1,258 
(66.0) 
Previous angina (%) 181 (27.2) 33 (35.1) 148 (25.9) NA NA NA 
Previous myocardial 
infarction (%) 
169 (25.4) 31 (33.0) 138 (24.2) 585 (23.7) 202 (35.8) 383 (20.1) 
Previous coronary 
intervention (%) 
161 (24.2) 30 (31.9) 131 (22.9) 604 (24.5) 200 (35.4) 404 (21.2) 
Hypertension (%) 309 (46.5) 55 (58.5) 254 (44.5)  1,524 
(61.7) 
447 (79.1) 1,077 
(56.5) 
Hyperlipidaemia (%) 252 (37.9) 50 (53.2) 202 (35.4) 1,225 
(49.6) 
400 (70.8) 825 (43.3) 
Type 1 diabetes 
mellitus (%) 
8 (1.2) 2 (2.1) 6 (1.1) 
415 (16.8) 157 (27.8) 258 (13.5) 
Type 2 diabetes 
mellitus (%) 
128 (19.2) 25 (26.6) 103 (18.0) 
Current smoking (%) 144 (21.7) 30 (31.9) 114 (20.0) 622 (25.2) 138 (24.4) 474 (25.4) 
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Time from symptom 
onset to arrival in 
the ED, n (%):* 
    
 
  
< 3h 
3 – 6h 
> 6h 
379 (57.0) 
153 (23.0) 
131 (19.7) 
47 (50.0) 
27 (28.7) 
19 (20.2) 
328 (58.1) 
126 (22.1) 
112 (19.6) 
584 (23.7) 
804 (32.7) 
1,071 
(43.6) 
121 (21.4) 
181 (32.0) 
263 (46.5) 
463 (24.4) 
623 (32.9) 
810 (42.7) 
* Time from symptom onset missing in 2 cases (testing study) 
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Table 2: Test characteristics of the Singulex Clarity hs-cTnI assay, used alone at the 
time of arrival in the ED in the testing and validation studies 
 Cut-off 
Study Patients 
‘ruled 
out’, n 
(%) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
For 
ACS 
LoD 
(0.08ng/L) 
Testing 0 (0.0) 
100.0 
(96.2 – 
100.0) 
0.0 
(0.0 – 0.6) 
14.1 
(14.1 – 14.1) 100.0 (N/A) 
Validation 6 (0.2) 
100.0 
(99.4 – 
100.0) 
0.3 
(0.1 – 0.7) 
22.9 
(21.2 – 24.6) 
100.0 
(N/A) 
0.8ng/L 
Testing 114 (17.1) 
97.9 
(92.5 – 99.7) 
19.6 
(16.4 – 23.1) 
16.7 
(16.0 – 17.4) 
98.3 
(93.4 – 99.6) 
Validation 706 (28.6) 
97.7 
(96.1 – 98.8) 
36.4 
(34.2 – 38.6) 
31.3 
(30.5 – 32.1) 
98.2 
(96.9 – 98.9) 
1.5ng/L 
Testing 267 (40.2) 
95.7 
(89.5 – 98.8) 
46.1 
(41.9 – 50.3) 
22.6 
(21.1 – 24.2) 
98.5 
(96.2 – 99.4) 
Validation 1,207 (48.9) 
90.6 
(87.9 – 92.9) 
60.6 
(58.3 – 62.8) 
40.5 
(39.1 – 42.0) 
95.6 
(94.4 – 96.6) 
99th 
percentile 
(8.67ng/L) 
Testing 548 (82.4) 
77.3 
(67.7 – 85.2) 
92.6 
(90.1 – 94.6) 
64.1 
(56.7 – 70.9) 
96.0 
(94.3 – 97.2) 
Validation 1,963 (79.5) 
63.5 
(59.4 – 67.5) 
92.2 
(90.9 – 93.4) 
70.8 
(67.2 -74.1) 
89.5 
(88.4 – 90.5) 
For 
AMI 
LoD 
(0.08ng/L) 
Testing 0 (0.0) 
100.0 
(95.3 – 
100.0) 
0.0 
(0.0 – 0.6) 
11.6 
(11.6 – 11.6) N/A 
Validation 6 (0.2) 
100.0 
(99.0 – 
100.0) 
0.3 
(0.1 – 0.6) 
15.1 
(15.1 – 15.2) 
100.0 
(N/A) 
0.8ng/L 
Testing 114 (17.1) 
100.0 
(95.3 – 
100.0) 
19.4 
(16.3 – 22.8) 
14.0 
(13.5 – 14.5) 
100.0 
(N/A) 
Validation 706 (28.6) 
99.7 
(98.5 – 
100.0) 
33.6 
(31.6 – 35.7) 
21.1 
(20.6 – 21.6) 
99.9 
(99.0 – 
100.0) 
1.5ng/L 
Testing 267 (40.2) 
98.7 
(93.0 – 
100.0) 
45.2 
(41.2 – 49.4) 
19.1 
(17.9 – 20.3) 
99.6 
(97.4 – 
100.0) 
Validation 1,207 (38.9) 
98.1 
(96.2 – 99.2) 
57.2 
(55.1 – 59.4) 
29.0 
(27.9  30.1) 
99.4 
(98.8 – 99.7) 
99th 
percentile 
(8.67ng/L) 
Testing 548 (82.4) 
87.0 
(77.4 – 94.0) 
91.5 
(88.9 – 93.6) 
57.3 
(50.4 – 63.9) 
98.2 
(96.8 – 99.0) 
Validation 1,963 (79.5) 
82.8 
(78.6 – 86.5) 
90.6 
(89.2 – 91.8) 
61.0 
(57.6 – 64.2) 
96.7 
(96.0 – 97.4) 
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Abbreviations: PPV= positive predictive value, NPV= negative predictive value, LR+= positive 
likelihood ratio, LR-= negative likelihood ration, ACS= acute coronary syndromes, AMI= acute 
myocardial infarction 
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Table 3: Test characteristics of the Singulex Clarity hs-cTnI measured at the time of 
arrival in the ED, in combination with ECG findings: rule-out only if hs-cTnI below 
the stated cut-off and no ECG ischaemia 
 Cut-off 
Study Patients 
‘ruled 
out’, n 
(%) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
For 
ACS 
0.8ng/L 
Testing 110  (16.5) 
97.9 
(92.5 – 99.7) 
18.9 
(15.8 – 22.4) 
16.6 
(15.9 – 17.3) 
98.2 
(93.1 – 99.5) 
Validation 663 (26.8) 
97.7 
(96.1 – 98.8) 
34.1 
(32.0 – 36.3) 
30.6 
(29.8 – 31.3) 
98.0 
(96.7 – 98.9) 
1.5ng/L 
Testing 254 (38.2) 
95.7 
(89.5 – 98.8) 
43.8 
(39.7 – 48.0) 
21.9 
(20.5 – 23.4) 
98.4 
(96.0 – 99.4) 
Validation 1,097 (44.4) 
92.2 
(89.7 – 94.3) 
55.3 
(53.0 – 57.5) 
38.0 
(36.7 – 39.3) 
96.0 
(94.7 – 97.0) 
99th 
percentile 
(8.67ng/L) 
Testing 517 (77.8) 
83.0 
(73.8 – 90.0) 
87.7 
(84.8 – 90.3) 
52.7 
(46.8 – 58.6) 
96.9 
(95.2 – 98.0) 
Validation 1,655 (67.0) 
76.5 
(72.7 – 79.9) 
79.9 
(78.0 – 81.7) 
53.0 
(50.5 – 55.5) 
92.0 
(90.8 – 93.0) 
For 
AMI 
0.8ng/L 
Testing 110  (16.5) 
100.0 
(95.3 – 100.0) 
18.7 
(15.6 – 22.1) 
13.9 
(13.4 – 14.3) 
100.0 
(N/A) 
Validation 663 (26.8) 
99.7 
(98.5 – 100.0) 
31.6 
(29.6 – 33.6) 
20.6 
(20.1 – 21.1) 
99.9 
(98.9 – 100.0) 
1.5ng/L 
Testing 254 (38.2) 
98.7 
(93.0 – 100.0) 
43.0 
(39.0 – 47.1) 
18.5 
(17.4 – 19.7) 
99.6 
(97.3 – 99.9) 
Validation 1,097 (44.4) 
89.0 
(85.4 – 92.0) 
77.0 
(75.1 – 78.8) 
40.7 
(38.7 – 42.8) 
97.5 
(96.7 – 98.1) 
99th 
percentile 
(8.67ng/L) 
Testing 517 (77.8) 
89.6 
(80.6 – 95.4) 
86.6 
(83.5 – 89.2) 
46.6 
(41.2 – 52.1) 
98.5 
(97.1 – 99.2) 
Validation 1,655 (67.0) 
89.0 
(85.4 – 92.0) 
77.0 
(75.1 – 78.8) 
40.7 
(38.7 – 42.8) 
97.5 
(96.7 – 98.1) 
 
 
